Uncategorized
Months after $100M series A, Syneron closes $150M round to support peptide platform
After securing a multibillion-dollar biobucks deal with AstraZeneca and raising nearly $100 million last year, peptide drug discovery company Syneron Bio has announced the closing of a $150 million series B round to support its macrocyclic peptide development platform.